-
1Academic Journal
Authors: Savchenko, O. A.
Source: Морфологія, Vol 13, Iss 3, Pp 120-125 (2019)
Morphologia; Том 13, № 3 (2019); 120-125Subject Terms: серозно-муцинозні пухлини, імуногістохімічний профіль, QH301-705.5, муцинозні пухлини, доброякісні та пограничні пухлини, 3. Good health, серозные опухоли, муцинозные опухоли, светлоклеточныe опухоли, серозно-муцинозные опухоли, опухоли Бреннера, доброкачественные и пограничные опухоли, высокодифференцированные карциномы яичника, иммуногистохимический профиль, serous tumors, mucinous tumors, light cell tumors, serous-mucinous tumors, Brenner tumors, benign and borderline tumors, highly differentiated ovarian carcinomas, immunohistochemical profile, серозні пухлини, високодиференційовані карциноми яєчника, світлоклітинні пухлини, пухлини бреннера, Biology (General), пухлини Бреннера
File Description: application/pdf
-
2Academic Journal
Source: Malignant tumours; Том 11, № 3s1 (2021); 16-18 ; Злокачественные опухоли; Том 11, № 3s1 (2021); 16-18 ; 2587-6813 ; 2224-5057
Subject Terms: нейроэндокринные опухоли, НЭО Grade 3, высокодифференцированные, высокозлокачественные
File Description: application/pdf
Relation: https://www.malignanttumors.org/jour/article/view/846/594; Pavel M, O’Toole D, Costa F, et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 2016;103:172– 85.; Sorbye, H., Welin, S ., Langer, S . W., Vestermark, L . W., Holt, N., Osterlund, P., Knigge, U. (2012). Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma ( WHO G3): The NORDIC NEC study. Annals of Oncology, 24 (1), 152–160; Shibuya, H., Hijioka, S., Sakamoto, Y., Ito, T., Ueda, K., Komoto, I., Okusaka, T. (2018). Multi-center clinical evaluation of streptozocinbased chemotherapy for advanced pancreatic neuroendocrine tumors in Japan: focus on weekly regimens and monotherapy. Cancer Chemotherapy and Pharmacology.; Dilz, L.-M., Denecke, T., Steffen, I. G., Prasad, V., von Weikersthal, L. F., Pape, U.-F., Pavel, M. (2015). Streptozocin / 5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours. European Journal of Cancer, 51 (10), 1253–1262; Ono, H., Kudo, A ., Akahoshi, K., Ogura, T., Ogawa, K., Ban, D., Tanabe, M. (2019). Combination of weekly streptozocin and oral S-1 treatment for patients of unresectable or metastatic pancreatic neuroendocrine neoplasms. Journal of Cancer Research and Clinical Oncology; Clewemar Antonodimitrakis , P.,Sundin, A, Wassberg, C., Granberg, D., Skogseid, B., & Eriksson, B. (2015). Streptozocin and 5 - Fluorouracil for the Treatment of Pancreatic Neuroendocrine Tumors: Efficacy, Prognostic Factors and Toxicity. Neuroendocrinology, 103 (3– 4), 345–353; Krug, S., Boch, M., Daniel, H., Nimphius, W., Müller, D., Michl, P., Gress, T. M. (2015). Streptozocin-Based Chemotherapy in Patients with Advanced Neuroendocrine Neoplasms — Predictive and Prognostic Markers for Treatment Stratification. PLOS ONE, 10 (12), e0143822.; Apostolidis , L .;DalBuono, A .; Merola, E.; Jann, H .; Jäger, D.; Wiedenmann, B.; Winkler, E. C.; Pavel, M. Multicenter Analysis of Treatment Outcomes for Systemic Therapy in Well Differentiated Grade 3 Neuroendocrine Tumors (NET G3). Cancers2021,13,1936; David L. Chan, Emily k. Bergsland, Jennifer A. Chan, Rujuta Gadgil, Thorvardur R. Halfdanarson, Kathleen Hornbacker, Virginia Kelly, Pamela L. Kunz, Patrick W. Mcgarrah, Nitya P. Raj, Diane L. Reidy, Alia Thawer, Julia Whitman, Linda Wu, Christoph Becker, Simron Singh. Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review. The Oncologist 2021;25:1– 6; Yerci O, Sehitoglu I, Ugras N, Cubukcu E, Yuce S, Bedir R , Cure E. Somatostatin receptor 2 and 5 expressionsin gastroenteropancreatic neuroendocrine tumors in Turkey. Asian Pac J Cancer Prev. 2015;16 (10):4377– 81.; Kanakis G, Grimelius L, Spathis A, Tringidou R, Rassidakis GZ, Öberg K, Kaltsas G, Tsolakis AV. Expression of Somatostatin Receptors 1–5 and Dopamine Receptor 2 in Lung Carcinoids: Implications for a Therapeutic Role. Neuroendocrinology. 2015;101 (3):211–22.; Suk-young Lee, Yoon Ji Choi1, Won Jin Chang, Sang Won Shin, Yeul Hong Kim, Seung Tae Kim. The role of chemotherapy and / or octreotide in patients with metastatic gastroenteropancreatic and hepatobiliary neuroendocrine carcinoma. Gastrointest Oncol 2014;5 (6):457– 462; Li J, Lu M, Lu Z, Li Z, Liu Y, Yang L, Li J, Zhang X, Zhou J, Wang X, Gong J, Gao J, Li Y, Shen L. Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study. Oncotarget. 2017 Apr 11;8 (15):25669 - 25678.; https://www.malignanttumors.org/jour/article/view/846